title: Association Between Statin Use and Endometrial Cancer Survival.
abstract: OBJECTIVE
  To evaluate the association of 3 hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor (statin) use and concordant polypharmacy with disease-specific survival from endometrial cancer.
  
  
  METHODS
  A retrospective cohort study was conducted of 985 endometrial cancer cases treated from January 1999 through December 2009 at a single institution. Disease-specific survival was estimated by Kaplan-Meier analyses. A Cox proportional hazards model was used to study factors associated with survival. All statistical tests were two-sided and performed using Stata.
  
  
  RESULTS
  At the time of analysis, 230 patients (22% of evaluable patients) died of disease and median follow-up was 3.28 years. Disease-specific survival was greater (179/220 [81%]) for women with endometrial cancer taking statin therapy at the time of diagnosis and staging compared with women not using statins (423/570 [74%]) (log rank test, P=.03). This association persisted for the subgroup of patients with nonendometrioid endometrial tumors who were statin users (59/87 [68%]) compared with nonusers (93/193 [43%]) (log rank test, P=.02). The relationship remained significant (hazard ratio 0.63, 95% confidence interval [CI] 0.40-0.99) after adjusting for age, clinical stage, radiation, and other factors. Further evaluation of polypharmacy showed an association between concurrent statin and aspirin use with an especially low disease-specific mortality (hazard ratio 0.25, 95% CI 0.09-0.70) relative to those who used neither.
  
  
  CONCLUSIONS
  Statin and aspirin use was associated with improved survival from nonendometrioid endometrial cancer.
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics & Gynecology and Women's Health, Montefiore Medical Center, and Albert Einstein Cancer Center and the Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York.
authors.forename: Nicole S
authors.initials: NS
authors.lastname: Nevadunsky
authors.forename: Anne
authors.initials: A
authors.lastname: Van Arsdale
authors.forename: Howard D
authors.initials: HD
authors.lastname: Strickler
authors.forename: Lori A
authors.initials: LA
authors.lastname: Spoozak
authors.forename: Alyson
authors.initials: A
authors.lastname: Moadel
authors.forename: Gurpreet
authors.initials: G
authors.lastname: Kaur
authors.forename: Eugenia
authors.initials: E
authors.lastname: Girda
authors.forename: Gary L
authors.initials: GL
authors.lastname: Goldberg
authors.forename: Mark H
authors.initials: MH
authors.lastname: Einstein
mesh_terms: D000328:Adult; D000368:Aged; D001241:Aspirin / Q000627:therapeutic use; D016889:Endometrial Neoplasms / Q000150:complications / Q000401:mortality*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy*; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D019338:Polypharmacy; D016016:Proportional Hazards Models; D012189:Retrospective Studies
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D001241:Aspirin